样式: 排序: IF: - GO 导出 标记为已读
-
Semaglutide, COVID-19 Mortality, and the Power of Harnessing Ongoing Clinical Trials During Unexpected Outbreaks J. Am. Coll. Cardiol. (IF 21.7) Pub Date : 2024-08-30 Jeremy Samuel Faust MD MS
-
Reflections From the Field: Ensuring Member Engagement J. Am. Coll. Cardiol. (IF 21.7) Pub Date : 2024-08-21 Cathleen Biga MS FACC, Juan Aranda MD FACC
-
Cardiac Index in Comatose Survivors of Out-of-Hospital Cardiac Arrest J. Am. Coll. Cardiol. (IF 21.7) Pub Date : 2024-08-12 Juan J. Russo MD, Paul Boland MD PhD, Jordan Bernick MSc, Pietro Di Santo MD, Derek Y.F. So MD, Benjamin Hibbert MD PhD, Christopher B. Fordyce MD MHS MSc, Sean van Diepen MD MSc, Christian Hassager MD DMSc, Michel R. Le May MD
-
Combined Surgical and Percutaneous Management of Circumflex Artery Occlusion After Minimally Invasive Mitral Valve Repair J. Am. Coll. Cardiol. (IF 21.7) Pub Date : 2024-08-12 Hristian Hinkov MD, Dustin Greve MD, Chong Bin Lee MD, Christoph Klein MD, Stephan Dreysse MD, Marian Kukucka MD, Serdar Akansel MD, Volkmar Falk MD PhD, Markus Kofler MD, Jörg Kempfert MD PhD
This report describes a hybrid intervention addressing left circumflex artery occlusion during minimally invasive mitral valve repair. By using a radiopaque Cor-Knot device (LSI Solutions), targeted removal of occluding sutures was achieved, circumventing sternotomy and coronary artery bypass. Real-time coronary angiography provided assessment of procedural success during surgical revision in a hybrid
-
Optimizing Management of Stable Angina: A Patient-Centered Approach Integrating Revascularization, Medical Therapy, and Lifestyle Interventions J. Am. Coll. Cardiol. (IF 21.7) Pub Date : 2024-08-12 Rocco A. Montone MD PhD, Riccardo Rinaldi MD, Giampaolo Niccoli MD PhD, Giuseppe Andò MD PhD, Felice Gragnano MD PhD, Raffaele Piccolo MD PhD, Francesco Pelliccia MD PhD, Elisabetta Moscarella MD PhD, Marco Zimarino MD PhD, Enrico Fabris MD PhD, Salvatore de Rosa MD PhD, Paolo Calabrò MD PhD, Italo Porto MD PhD, Francesco Burzotta MD PhD, Francesco Grigioni MD PhD, Emanuele Barbato MD PhD, Alaide Chieffo
Angina pectoris may arise from obstructive coronary artery disease (CAD) or in the absence of significant CAD (ischemia with nonobstructed coronary arteries [INOCA]). Therapeutic strategies for patients with angina and obstructive CAD focus on reducing cardiovascular events and relieving symptoms, whereas in INOCA the focus shifts toward managing functional alterations of the coronary circulation.
-
Clinical and Analytical Performance of a Novel Point-of-Care High-Sensitivity Cardiac Troponin I Assay J. Am. Coll. Cardiol. (IF 21.7) Pub Date : 2024-08-12 Luca Koechlin MD, Jasper Boeddinghaus MD, Pedro Lopez-Ayala MD, Cornelia Reber MD, Thomas Nestelberger MD, Karin Wildi MD PhD, Carlos C. Spagnuolo MD, Ivo Strebel PhD, Jonas Glaeser MD, Paolo Bima MD, Luca Crisanti MD, Lourdes Herraiz-Recuenco MSc, Elisa Dubach MS, Òscar Miró MD, F. Javier Martin-Sanchez MD, Damian Kawecki MD, Dagmar I. Keller MD, Michael Christ MD, Andreas Buser MD, Maria Rubini Giménez
Point-of-care (POC) high-sensitivity cardiac troponin assays may further accelerate the diagnosis of myocardial infarction (MI). This study sought to assess the clinical and analytical performance of the novel high-sensitivity cardiac troponin I (hs-cTnI)-SPINCHIP POC test. Adult patients presenting with acute chest discomfort to the emergency department were enrolled in an international, diagnostic
-
Point-of-Care High-Sensitivity Troponin Testing in the Emergency Department: The Way of the Future? J. Am. Coll. Cardiol. (IF 21.7) Pub Date : 2024-08-12 Aldo Clerico MD, Alberto Aimo MD PhD, Claudio Passino MD PhD
-
Bridging the Gap: Tackling Global Challenges and Seizing Opportunities to Improve Access to CV Care J. Am. Coll. Cardiol. (IF 21.7) Pub Date : 2024-08-12 Cathleen Biga MSN FACC
-
Cardiovascular Care in the United States: Penny Wise and Pound Foolish J. Am. Coll. Cardiol. (IF 21.7) Pub Date : 2024-08-12 Tariq Ahmad MD MPH, Nihar R. Desai MD MPH, Sara Tabtabai MD
-
Acute Brain Infarctions and Periprocedural Stroke: Implications for Evaluating Cerebral Embolic Protection Devices J. Am. Coll. Cardiol. (IF 21.7) Pub Date : 2024-08-12 Samir Kapadia MD, Amar Krishnaswamy MD, Michael Mack MD
-
Clinical Significance of Diffusion-Weighted Brain MRI Lesions After TAVR: Results of a Patient-Level Pooled Analysis J. Am. Coll. Cardiol. (IF 21.7) Pub Date : 2024-08-12 Alexandra J. Lansky MD, Daniel Grubman MD, Michael G. Dwyer III PhD, Robert Zivadinov MD PhD, Helen Parise ScD, Jeffrey W. Moses MD, Tayyab Shah MD, Cody Pietras BA, Daniela Tirziu PhD, Louise Gambone RN, Martin B. Leon MD, Tamim M. Nazif MD, Steven R. Messé MD
Acute brain infarction detected by diffusion-weighted magnetic resonance imaging (DW-MRI) is common after transcatheter aortic valve replacement (TAVR), but its clinical relevance is uncertain. The authors investigated the relationship between DW-MRI total lesion number (TLN), individual lesion volume (ILV), and total lesion volume (TLV) and clinical stroke outcomes after TAVR. Patient-level data were
-
Kidney and Cardiovascular Outcomes With SGLT2 Inhibitors and/or GLP-1 Receptor Agonists in Type 2 Diabetes J. Am. Coll. Cardiol. (IF 21.7) Pub Date : 2024-08-12 Brendon L. Neuen MBBS MSc PhD, Scott D. Solomon MD
-
Kidney and Cardiovascular Effectiveness of SGLT2 Inhibitors vs GLP-1 Receptor Agonists in Type 2 Diabetes J. Am. Coll. Cardiol. (IF 21.7) Pub Date : 2024-08-12 Daniel Edmonston MD MHS, Hillary Mulder MS, Elizabeth Lydon MS, Karen Chiswell PhD, Zachary Lampron MPH, Christina Shay PhD, Keith Marsolo PhD, Raj C. Shah MD, W. Schuyler Jones MD, Howard Gordon MD, Wenke Hwang PhD, Isabella Ayoub MD MPH, Daniel Ford MD MPH, Alanna Chamberlain PhD, Ajaykumar Rao MD MMSc, Vivian Fonseca MD, Alexander Chang MD MS, Faraz Ahmad MD MS, Adriana Hung MD MPH, Kelly Hunt PhD
Emerging data suggest that glucagon-like peptide-1 receptor agonists (GLP-1 RAs) improve kidney outcomes for people with type 2 diabetes (T2D). Direct comparisons of the kidney and cardiovascular effectiveness of GLP-1 RA with sodium-glucose cotransporter 2 inhibitors (SGLT2i), a first-line therapy for this population, are needed. The authors compared kidney and cardiovascular outcomes for new users
-
Prescription Patterns for Sodium-Glucose Cotransporter 2 Inhibitors in U.S. Health Systems J. Am. Coll. Cardiol. (IF 21.7) Pub Date : 2024-08-12 Jung-Im Shin MD PhD, Yunwen Xu PhD, Alexander R. Chang MD MS, Juan J. Carrero PharmD PhD, Carina M. Flaherty BA, Amrita Mukhopadhyay MD MS, Lesley A. Inker MD MS, Saul B. Blecker MD MHS, Leora I. Horwitz MD MHS, Morgan E. Grams MD PhD
Sodium-glucose cotransporter 2 (SGLT2) inhibitors reduce heart failure (HF) hospitalizations, recurrent cardiovascular events, and chronic kidney disease (CKD) progression, and thus constitute a Class 1a recommendation in people with diabetes and atherosclerotic cardiovascular disease, HF, or CKD and in people with severe albuminuria or HF, regardless of diabetes status. The purpose of this study was
-
2024 Update to the 2020 ACC/AHA Clinical Performance and Quality Measures for Adults With Heart Failure: A Report of the American Heart Association/American College of Cardiology Joint Committee on Performance Measures J. Am. Coll. Cardiol. (IF 21.7) Pub Date : 2024-08-08 Writing Committee Members, Michelle M. Kittleson MD PhD FACC FAHA FHFSA, Khadijah Breathett MD MS FACC FAHA FHFSA, Boback Ziaeian MD PhD FACC FAHA, David Aguilar MD MSc FAHA, Vanessa Blumer MD, Biykem Bozkurt MD PhD FACC FAHA FHFSA, Rebecca L. Diekemper MPH, Michael P. Dorsch PharmD MS FACC FAHA, Paul A. Heidenreich MD MS FACC FAHA, Corrine Y. Jurgens PhD RN ANP FAHA FHFSA, Prateeti Khazanie MD MPH
-
Should the SELECT Trial Make Us Comfortable Using GLP-1 Receptor Agonists in HFrEF? J. Am. Coll. Cardiol. (IF 21.7) Pub Date : 2024-08-07 João Sérgio Neves MD PhD, Faiez Zannad MD PhD, Javed Butler MD MPH, Milton Packer MD, João Pedro Ferreira MD PhD
-
Patch Wearable Defibrillator: Excellent Therapy, But Patient Acceptance Is a Sticky Issue J. Am. Coll. Cardiol. (IF 21.7) Pub Date : 2024-07-29 Emile G. Daoud MD
-
Shining a New Light Into the Black Box: From Reserve to Resistance, to Resistance Reserve J. Am. Coll. Cardiol. (IF 21.7) Pub Date : 2024-07-29 Tim P. van de Hoef MD PhD
-
Pericardial Diseases and Best Practices for Pericardiectomy: JACC State-of-the-Art Review J. Am. Coll. Cardiol. (IF 21.7) Pub Date : 2024-07-29 Mohamed Al-Kazaz MD, Allan L. Klein MD, Jae K. Oh MD, Juan A. Crestanello MD, Paul C. Cremer MD MS, Michael Z. Tong MD, Marijan Koprivanac MD, Valentin Fuster MD PhD, Ismail El-Hamamsy MD PhD, David H. Adams MD, Douglas R. Johnston MD
Remarkable advances have occurred in the understanding of the pathophysiology of pericardial diseases and the role of multimodality imaging in this field. Medical therapy and surgical options for pericardial diseases have also evolved substantially. Pericardiectomy is indicated for chronic or irreversible constrictive pericarditis, refractory recurrent pericarditis despite optimal medical therapy,
-
Abdominal Aortic Aneurysm-Attributed Mortality in the United States J. Am. Coll. Cardiol. (IF 21.7) Pub Date : 2024-07-29 Marco Zuin MD MS, Rahul Aggarwal MD, Behnood Bikdeli MD MS, Lee Kirksey MD MBA, Mohamad A. Hussain MD PhD, Marco J. Bilato MD, Claudio Bilato MD PhD, Gregory Piazza MD MS
-
Effect of Time-Varying Exposure to School-Based Health Promotion on Adiposity in Childhood J. Am. Coll. Cardiol. (IF 21.7) Pub Date : 2024-07-29 Gloria Santos-Beneit PhD, Patricia Bodega MS, Amaya de Cos-Gandoy MS, Mercedes de Miguel MS, Carla Rodríguez MS, Xavier Orrit PhD, Vanesa Carral PhD, Domingo Haro BS, Isabel Carvajal MS, Carlos Peyra BA, Jesús Martínez-Gómez MS, Juan Miguel Fernández-Alvira PhD, Rodrigo Fernández-Jiménez MD PhD, Valentin Fuster MD PhD
The results of most school-based health promotion initiatives are inconclusive. This trial assessed the effect of time-varying exposures to a multicomponent school-based health promotion intervention (SI! Program) on adiposity markers. A total of 48 schools in Madrid (Spain) were cluster randomized to receive the SI! Program through elementary education grades 1 to 6 (E1-6, 12 schools, 459 children)
-
Intervention in School-Aged Children to Prevent Progression of Obesity and Cardiometabolic Disease: A Paradigm Shift Indeed J. Am. Coll. Cardiol. (IF 21.7) Pub Date : 2024-07-29 Carl J. Lavie MD, Ian J. Neeland MD, Francisco B. Ortega PhD
-
Plasma Proteomic Biomarkers of Aortic Stenosis: A Mendelian Randomization Study J. Am. Coll. Cardiol. (IF 21.7) Pub Date : 2024-07-29 Ta-Yu Yang MS, Aeron M. Small MD MTR, Line Dufresne MS, Gina M. Peloso PhD, Pradeep Natarajan MD MMSc, James C. Engert PhD, George Thanassoulis MD MSc
-
Inquiries Into the Mechanisms by Which GLP-1 Receptor Agonists Reduce Cardiovascular Risk in Diabetes J. Am. Coll. Cardiol. (IF 21.7) Pub Date : 2024-07-29 Silvio E. Inzucchi MD, Andrew E. Arai MD
-
Liraglutide Improves Myocardial Perfusion and Energetics and Exercise Tolerance in Patients With Type 2 Diabetes J. Am. Coll. Cardiol. (IF 21.7) Pub Date : 2024-07-29 Amrit Chowdhary PhD, Sharmaine Thirunavukarasu PhD, Tobin Joseph BSc, Nicholas Jex PhD, Sindhoora Kotha MBBS, Marilena Giannoudi MSc MRCP MBBS, Henry Procter MBBS, Lizette Cash BSc, Sevval Akkaya BSc, David Broadbent PhD, Hui Xue PhD, Peter Swoboda PhD, Ladislav Valkovič PhD, Peter Kellman PhD, Sven Plein PhD, Oliver J. Rider DPhil, Stefan Neubauer MD, John P. Greenwood PhD, Eylem Levelt DPhil
Type 2 diabetes (T2D) is characterized by insulin resistance (IR) and dysregulated insulin secretion. Glucagon-like peptide-1 receptor agonist liraglutide promotes insulin secretion, whereas thiazolidinedione-pioglitazone decreases IR. This study aimed to compare the efficacies of increasing insulin secretion vs decreasing IR strategies for improving myocardial perfusion, energetics, and function in
-
A Patch Wearable Cardioverter-Defibrillator for Patients at Risk of Sudden Cardiac Arrest J. Am. Coll. Cardiol. (IF 21.7) Pub Date : 2024-07-29 John Hummel MD, Mahmoud Houmsse MD, Gery Tomassoni MD, Devi Nair MD, Jorge Romero MD, Joe Hargrove MD, Kiran Mathews MS, Anjali B. Thakkar MD MBA, Steven Ullery MS, Zubin J. Eapen MD MHS, Uday N. Kumar MD, Roxana Mehran MD, Javed Butler MD, Jewel IDE Study Investigators, Joe L. Hargrove M.D., Joseph Surber M.D., Bruce Goldner M.D., Gery Tomassoni M.D., James Stone M.D., Faisal Wahid M.D., Mikhael El-Chami
For many patients, sudden cardiac arrest (SCA) risk is elevated temporarily. Wearable cardioverter-defibrillators (WCDs) can monitor and treat SCA during these temporary periods. Traditional WCDs can be uncomfortable, require frequent maintenance, and cannot be used when showering, resulting in poor compliance and avoidable SCA deaths. The Jewel is a novel, water-resistant patch–wearable cardioverter-defibrillator
-
Exercise Testing to Unmask Latent LVOT Obstruction in a Highly Symptomatic Patient With Hypertrophic Cardiomyopathy J. Am. Coll. Cardiol. (IF 21.7) Pub Date : 2024-07-03 Mustafa Husaini MD MBA, Richard G. Bach MD, Sharon Cresci MD
Rest imaging in hypertrophic cardiomyopathy may underestimate or miss left ventricular outflow tract obstruction, leading to suboptimal management decisions that negatively affect symptomatic patients. The 2024 hypertrophic cardiomyopathy guidelines describe exercise stress testing as an important tool to determine overall exercise tolerance and latent, exercise-provoked left ventricular outflow tract
-
Private Equity in Cardiovascular Practice: Solution or Symptom? J. Am. Coll. Cardiol. (IF 21.7) Pub Date : 2024-06-30 Edward T.A. Fry MD
-
Private Equity Acquisitions of Outpatient Cardiology Practices in the United States, 2013-2023 J. Am. Coll. Cardiol. (IF 21.7) Pub Date : 2024-06-30 Victoria L. Bartlett MD, Michael Liu MPhil, Shylie Ati BA, Robert W. Yeh MD MSc, Zhaonian Zheng MSc, Rishi K. Wadhera MD MPP MPhil
-
-
The FDA and the Cardiovascular Community J. Am. Coll. Cardiol. (IF 21.7) Pub Date : 2024-06-24 Haider J. Warraich MD, Robert M. Califf MD
-
The Editorship of the Journal of the American College of Cardiology: Passing the Torch J. Am. Coll. Cardiol. (IF 21.7) Pub Date : 2024-06-24 Eugene Braunwald MD
-
Inflammation, Colchicine, and Atherosclerotic Disease: Is Familial Mediterranean Fever an Exception That Proves the Rule? J. Am. Coll. Cardiol. (IF 21.7) Pub Date : 2024-06-24 Eldad Ben-Chetrit MD, Mark Nidorf MD, Rodney Falk MD, Paul M Ridker MD
-
Transforming Cardiovascular Care With Artificial Intelligence: From Discovery to Practice: JACC State-of-the-Art Review J. Am. Coll. Cardiol. (IF 21.7) Pub Date : 2024-06-24 Rohan Khera MD MS, Evangelos K. Oikonomou MD DPhil, Girish N. Nadkarni MD MPH, Jessica R. Morley PhD, Jenna Wiens PhD, Atul J. Butte MD PhD, Eric J. Topol MD
-
Lessons for Cardiovascular Clinical Investigators: The Tumultuous 2,500-Year Journey of Physicians Who Ignited Our Fire J. Am. Coll. Cardiol. (IF 21.7) Pub Date : 2024-06-24 Milton Packer MD
-
Efficacy of Semaglutide by Sex in Obesity-Related Heart Failure With Preserved Ejection Fraction: STEP-HFpEF Trials J. Am. Coll. Cardiol. (IF 21.7) Pub Date : 2024-06-23 Subodh Verma MD PhD, Javed Butler MD, Barry A. Borlaug MD, Melanie Davies MD, Dalane W. Kitzman MD, Sanjiv J. Shah MD, Mark C. Petrie MD, Eric Barros MD, Cecilia Rönnbäck MD PhD, Lene Sommer Vestergaard MSc, Morten Schou MD PhD, Justin A. Ezekowitz MBBCh MSc, Kavita Sharma MD, Shachi Patel PhD, Khaja M. Chinnakondepalli MS, Mikhail N. Kosiborod MD, STEP-HFpEF Trial Committees and Investigators
More women than men have heart failure with preserved ejection fraction (HFpEF). The purpose of this study was to assess baseline characteristics and treatment effect of semaglutide by sex across the STEP-HFpEF (Research Study to Investigate How Well Semaglutide Works in People Living With Heart Failure and Obesity) program. In a prespecified secondary analysis of pooled data from STEP-HFpEF and STEP-HFpEF
-
Incretin-Based Therapies in Women With Obesity-Related HFpEF: Time to STEP Into a Paradigm of Integrated Care J. Am. Coll. Cardiol. (IF 21.7) Pub Date : 2024-06-23 John W. Ostrominski MD, Anuradha Lala MD
-
Heart Failure With Preserved Ejection Fraction: Prioritizing Patients’ Symptoms J. Am. Coll. Cardiol. (IF 21.7) Pub Date : 2024-06-23 Antonio Cannata MD, Daniel I. Bromage MB BS PhD, Susan E. Piper MB BS MD, Theresa A. McDonagh MB ChB MD
-
Semaglutide and NYHA Functional Class in Obesity-Related Heart Failure With Preserved Ejection Fraction: The STEP-HFpEF Program J. Am. Coll. Cardiol. (IF 21.7) Pub Date : 2024-06-23 Morten Schou MD, Mark C. Petrie MD, Barry A. Borlaug MD, Javed Butler MD, Melanie J. Davies MD, Dalane W. Kitzman MD, Sanjiv J. Shah MD, Subodh Verma MD PhD, Shachi Patel PhD, Khaja M. Chinnakondepalli MS, Signe Harring MD PhD, Steen Z. Abildstrøm PhD, Karoline Liisberg PhD, Mikhail N. Kosiborod MD, STEP-HFpEF Trial Committees and Investigators
In the Semaglutide Treatment Effect in People with obesity and HFpEF (STEP-HFpEF) program, semaglutide improved heart failure (HF)-related symptoms, physical limitations, and exercise function, and reduced bodyweight in patients with obesity-related heart failure with preserved ejection fraction (HFpEF). Whether semaglutide improves functional status, as assessed by NYHA functional class, is unknown
-
Adverse Cardiovascular Outcomes in Patients With Obstructive Sleep Apnea and Obesity: Metabolic Surgery vs Usual Care J. Am. Coll. Cardiol. (IF 21.7) Pub Date : 2024-06-21 Ali Aminian MD, Lu Wang MS, Abdullah Al Jabri MD, Rickesha Wilson MD, James Bena MS, Alex Milinovich BA, Jian Jin MS, Catherine Heinzinger DO, Cinthya Pena-Orbea MD, Nancy Foldvary-Schaefer DO MS, Steven E. Nissen MD, Reena Mehra MD MS
No therapy has been shown to reduce the risk of major adverse cardiovascular events (MACE) and death in patients with obstructive sleep apnea (OSA). The authors sought to investigate the long-term relationship between metabolic surgery and incident MACE in patients with OSA and obesity. Adult patients with a body mass index 35 to 70 kg/m and moderate-to-severe OSA at a U.S. health system (2004-2018)
-
Cardiovascular Health, Juneteenth 2024: Are We Thriving Together or Not? J. Am. Coll. Cardiol. (IF 21.7) Pub Date : 2024-06-18 Jennifer H. Mieres MD, Jeffrey T. Kuvin MD, Robert O. Roswell MD
-
Excess Cardiovascular Mortality Among Black Americans 2000-2022 J. Am. Coll. Cardiol. (IF 21.7) Pub Date : 2024-06-18 Adith S. Arun BS, Mitsuaki Sawano MD PhD, Yuan Lu ScD, Frederick Warner PhD, César Caraballo MD, Rohan Khera MD MS, Melvin R. Echols MD, Clyde W. Yancy MD, Harlan M. Krumholz MD SM
-
A Time for Reflection: 10 Years With JACC J. Am. Coll. Cardiol. (IF 21.7) Pub Date : 2024-06-17 Valentin Fuster MD PhD
-
Timing of P2Y12 Inhibitor Administration in Patients With STEMI Undergoing Primary PCI J. Am. Coll. Cardiol. (IF 21.7) Pub Date : 2024-06-17 Manuel Almendro-Delia MD PhD, Begoña Hernández-Meneses MD, Gloria Padilla-Rodríguez MD, Emilia Blanco-Ponce MD PhD, Jose Andres Arboleda-Sánchez MD, Juan Carlos Rodríguez-Yáñez MD PhD, José Manuel Soto-Blanco MD, Isabel Fernández-García MD, José M. Castillo-Caballero MD, Juan C. García-Rubira MD PhD, Rafael Hidalgo-Urbano MD PhD
-
Antiplatelet Therapy, Pretreatment, and Primary PCI: Every Minute Counts J. Am. Coll. Cardiol. (IF 21.7) Pub Date : 2024-06-17 Johanne Silvain MD PhD, Gilles Montalescot MD PhD, Paul Guedeney MD PhD
-
Randomized Trial of a Vascular Care Team vs Education for Patients With Peripheral Artery Disease J. Am. Coll. Cardiol. (IF 21.7) Pub Date : 2024-06-17 Connie N. Hess MD MHS, Ashley Daffron PharmD, Mark R. Nehler MD, Justin T. Morrison MD, Cullen E. Buchanan MD, Michael Szarek PhD MS, Victoria E. Anderson MPH, Christopher P. Cannon MD, Judith Hsia MD, Joseph J. Saseen PharmD, Marc P. Bonaca MD MPH
-
Team-Based Care to Overcome Therapeutic Inertia in PAD: A Step in the Right Direction J. Am. Coll. Cardiol. (IF 21.7) Pub Date : 2024-06-17 Dave L. Dixon PharmD, Anurag Mehta MD, Gregory Moneta MD
-
Fueling the Fire: Autoimmunity and Atherosclerosis J. Am. Coll. Cardiol. (IF 21.7) Pub Date : 2024-06-17 Brittany N. Weber MD PhD, Ron Blankstein MD
-
Association of Autoimmune Diseases With Coronary Atherosclerosis Severity and Ischemic Events J. Am. Coll. Cardiol. (IF 21.7) Pub Date : 2024-06-17 Martin Bødtker Mortensen MD PhD, Jesper Møller Jensen MD PhD, Niels Peter Rønnow Sand MD PhD, Kristian Kragholm MD PhD, Michael J. Blaha MD MPH, Erik Lerkevang Grove MD PhD, Henrik Toft Sørensen MD DMSc, Kevin Olesen MD PhD, Michael Maeng MD PhD, Brian Løgstrup MD PhD, Martin Busk MD PhD, Ellen Margrethe Hauge MD PhD, Ann Marie Navar MD PhD, Hans Erik Bøtker MD DMSc, Bjarne Linde Nørgaard MD PhD
-
Intravenous Iron Repletion for Patients With Heart Failure and Iron Deficiency: JACC State-of-the-Art Review J. Am. Coll. Cardiol. (IF 21.7) Pub Date : 2024-06-17 Baljash Cheema MD MSCI MSAI, Anuj Chokshi MD, Olusola Orimoloye MD MPH, Hossein Ardehali MD PhD
-
Early Renal Dysfunction in Middle-Aged Adults Predicts Fatal and Nonfatal Cardiovascular Events J. Am. Coll. Cardiol. (IF 21.7) Pub Date : 2024-06-17 Yap-Hang Chan MBBS, Jie V. Zhao PhD, Shiu-Lun Au Yeung PhD, Yuen-Kwun Wong PhD, Ka-Wing Au PhD, Aimin Xu PhD, Tai-Hing Lam MD, Bernard M.Y. Cheung PhD, Karen Siu-Ling Lam MD, Hung-Fat Tse MD PhD
-
Addressing the Global Burden of Cardiovascular Disease in Women: JACC State-of-the-Art Review J. Am. Coll. Cardiol. (IF 21.7) Pub Date : 2024-06-17 Dominique Vervoort MD MPH MBA, Ruoting Wang MSc, Guowei Li PhD, Lynaea Filbey MD, Omosivie Maduka MBBS MScPH, LaPrincess C. Brewer MD MPH, Mamas A. Mamas DPhil, Maria Cecilia Bahit MD, Sofia B. Ahmed MD MMSc, Harriette G.C. Van Spall MD MPH
-
Evaluating Long-Term Care After ST-Segment Elevation Myocardial Infarction With a Population-Based Comprehensive Medical Record J. Am. Coll. Cardiol. (IF 21.7) Pub Date : 2024-06-17 Myron L. Weisfeldt MD, Stephen D. Sisson MD
-
10-Year Mortality After ST-Segment Elevation Myocardial Infarction Compared to the General Population J. Am. Coll. Cardiol. (IF 21.7) Pub Date : 2024-06-17 Pernille Gro Thrane MD, Kevin Kris Warnakula Olesen MD PhD, Troels Thim MD PhD, Christine Gyldenkerne MD, Malene Kærslund Hansen MD, Nina Stødkilde-Jørgensen MD, Lars Jakobsen MD, Martin Bødtker Mortensen MD PhD, Steen Dalby Kristensen MD DMSci, Michael Maeng MD PhD
-
The Quest for Understanding Diabetic Cardiomyopathy: Can We Preserve Function and Prevent Failure? J. Am. Coll. Cardiol. (IF 21.7) Pub Date : 2024-06-17 Anuradha Lala MD, Robert J. Mentz MD, Carlos G. Santos-Gallego MD
-
Anticoagulants in Subclinical Atrial Fibrillation: Beginning to Define the Treatment Paradigm J. Am. Coll. Cardiol. (IF 21.7) Pub Date : 2024-05-22 Sachin J. Shah MD MPH
-
ALARA in Atrial Fibrillation: Redefining Ablation Success J. Am. Coll. Cardiol. (IF 21.7) Pub Date : 2024-05-22 Peter Hanna MD PhD, Carlos Macias MD, Eric Buch MD MS
-
Apixaban vs Aspirin According to CHA2DS2-VASc Score in Subclinical Atrial Fibrillation: Insights From ARTESiA J. Am. Coll. Cardiol. (IF 21.7) Pub Date : 2024-05-19 Renato D. Lopes MD PhD, Christopher B. Granger MD, Daniel M. Wojdyla MS, William F. McIntyre MD PhD, Marco Alings MD, Thenmozhi Mani PhD, Chinthanie Ramasundarahettige MSc, Lena Rivard MD MSc, Dan Atar MD, David H. Birnie MD, Giuseppe Boriani MD PhD, Guy Amit MD MPH, Peter Leong-Sit MD MSc, Claus Rinne MD, Gabor Z. Duray MD PhD, Michael R. Gold MD PhD, Stefan H. Hohnloser MD, Valentina Kutyifa MD PhD
ARTESiA (Apixaban for the Reduction of Thrombo-Embolism in Patients With Device-Detected Sub-Clinical Atrial Fibrillation) demonstrated that apixaban, compared with aspirin, significantly reduced stroke and systemic embolism (SE) but increased major bleeding in patients with subclinical atrial fibrillation. To help inform decision making, the authors evaluated the efficacy and safety of apixaban according
-
Pulsed Field vs Conventional Thermal Ablation for Paroxysmal Atrial Fibrillation: Recurrent Atrial Arrhythmia Burden J. Am. Coll. Cardiol. (IF 21.7) Pub Date : 2024-05-18 Vivek Y. Reddy MD, Moussa Mansour MD, Hugh Calkins MD, Andre d'Avila MD PhD, Larry Chinitz MD, Christopher Woods MD PhD, Sanjaya K. Gupta MD, Jamie Kim MD, Zayd A. Eldadah MD PhD, Robert A. Pickett MD, Jeffrey Winterfield MD, Wilber W. Su MD, Jonathan W. Waks MD, Christopher W. Schneider MEng, Elizabeth Richards MS, Elizabeth M. Albrecht PhD, Brad S. Sutton MD, Edward P. Gerstenfeld MD, ADVENT Investigators
-
Real-World 1-Year Results of Tricuspid Edge-to-Edge Repair From the bRIGHT Study J. Am. Coll. Cardiol. (IF 21.7) Pub Date : 2024-05-15 Philipp Lurz MD PhD, Karl-Philipp Rommel MD, Thomas Schmitz MD, Raffi Bekeredjian MD, Georg Nickenig MD, Helge Möllmann MD, Ralph Stephan von Bardeleben MD, Alexander Schmeisser MD, Iskandar Atmowihardjo MD, Rodrigo Estevez-Loureiro PhD MD, Edith Lubos MD, Megan Heitkemper PhD, Kelli Peterman MPH, Harald Lapp MD, Erwan Donal MD
Severe tricuspid regurgitation (TR) is known to be associated with poor quality of life and increased risk of death when left untreated. We sought to report the 1-year clinical outcomes of subjects treated by tricuspid transcatheter edge-to-edge repair (TEER) with the TriClip system (Abbott Cardiovascular) in a contemporary real-world setting. The bRIGHT (An Observational Real-World Study Evaluating